Patient Population and Treatment
T2c, adenocarcinoma of the prostate, Cancer
SEMINAL VESICLES, ONCOLOGY, ADENOCARCINOMA OF THE PROSTATE, CANCER
Between September 21, 2005, and January 13, 2015, 350 patients from both academic and community-based health centers in the United States, Australia, and New Zealand who has been diagnosed with the 2002 American Joint Commission on Cancer Clinical Stage T1b-T4N0M0 adenocarcinoma of the prostate with at least 1 unfavorable prognostic factor were included in this study. Unfavorable prognostic factors included (1) clinical T2c to T4 or (2) clinical T1b to T2b and 1 of the following: PSA level of more than 10 ng/mL (to convert to ug/L, multiply by 1.0), biopsy Gleason score of 4 + 3 or higher, tertiary grade 5 PC, biopsy Gleason score of 3 + 4 with at least 50% of biopsy cores positive, PSA velocity of more than 2 ng/mL/y, or biopsy or radiographic evidence of seminal vesicle invasion. Additional inclusion criteria included being 30 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and having adequate hematologic function with a white blood cell count more than 3000/mmAs shown in 